{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04462055",
      "orgStudyIdInfo": {
        "id": "19-197"
      },
      "organization": {
        "fullName": "UMC Utrecht",
        "class": "OTHER"
      },
      "briefTitle": "Effectiveness of Dupilumab in Food Allergic Patients With Moderate to Severe Atopic Dermatitis",
      "officialTitle": "Effectiveness of Dupilumab in Food Allergic Patients With Moderate to Severe Atopic Dermatitis"
    },
    "statusModule": {
      "statusVerifiedDate": "2022-07",
      "overallStatus": "TERMINATED",
      "whyStopped": "Not feasible to include patients (due to e.g. COVID-19, patients with severe reactions not willing to undergo 2 food challenges, lower number of eligible patients than expected)",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2019-05-01",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2022-07-01",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2022-07-01",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2020-06-17",
      "studyFirstSubmitQcDate": "2020-07-03",
      "studyFirstPostDateStruct": {
        "date": "2020-07-08",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2022-07-27",
      "lastUpdatePostDateStruct": {
        "date": "2022-07-29",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "PRINCIPAL_INVESTIGATOR",
        "investigatorFullName": "Dr M.S. de Bruin-Weller",
        "investigatorTitle": "Principal Investigator",
        "investigatorAffiliation": "UMC Utrecht"
      },
      "leadSponsor": {
        "name": "UMC Utrecht",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": true,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "This study evaluates the effectiveness of Dupilumab in food allergic patients with moderate to severe Atopic Dermatitis (AD). Included patients participated in the BioDay Registry.",
      "detailedDescription": "The positive results of the dupilumab studies in AD, asthma and nasal polyposis with chronic sinusitis validate the fundamental role for IL-4 and IL-13 in the pathogenesis of these diseases, and add to the possibility that these cytokines are also critically involved in other related allergic/atopic (type 2 immune) diseases that are often co-morbidly associated with AD, such as food allergy."
    },
    "conditionsModule": {
      "conditions": [
        "Food Allergy"
      ],
      "keywords": [
        "Dupilumab",
        "Food allergy",
        "Atopic Dermatitis",
        "BioDay Registry"
      ]
    },
    "designModule": {
      "studyType": "OBSERVATIONAL",
      "patientRegistry": true,
      "targetDuration": "3 Years",
      "designInfo": {
        "observationalModel": "COHORT",
        "timePerspective": "PROSPECTIVE"
      },
      "bioSpec": {
        "retention": "SAMPLES_WITHOUT_DNA",
        "description": "Blood"
      },
      "enrollmentInfo": {
        "count": 3,
        "type": "ACTUAL"
      }
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "To evaluate the effect of Dupilumab on change in clinical eliciting dose (i.e. lowest dose causing an allergic reaction) in subjects with peanut, hazelnut, walnut, cow's milk, hen's egg and/or soybean allergy",
          "description": "AD patients with moderate to severe AD who are indicated for treatment with dupilumab and have symptomatic food allergy to peanut, hazelnut, walnut, cow's milk, hen's egg and/or soybean allergy will be included.",
          "timeFrame": "Each subject will undergo two oral food challenges: one at screening and one during dupilumab treatment with a treatment duration of at least 28 weeks."
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "To evaluate the effect of Dupilumab on food allergy related quality of life",
          "description": "The food allergy related quality of life will be measured with the Food allergy Quality of Life Questionnaire adult form (FAQLQ-AF)\n\nThe FAQLQ-AF assesses health-related quality of life (HRQL) and contains a total of 29 items. The total FAQLQ-AF score is the mean score of all items with a range of 1 'no impairment' to 7 'maximal impairment'.",
          "timeFrame": "Before the first food challenge and 3 months after the second food challenge during their visit conform Bioday protocol."
        },
        {
          "measure": "To evaluate the effect of Dupilumab on the level of specific IgE (sIgE) antibodies",
          "description": "sIgE in blood will be measured using the ImmunoCAP system (Thermofisher, Uppsala, Sweden). Levels of â‰¥ 0.35 kU/L will be considered positive. Depending on the food the following will be tested: peanut: extract, Ara h 2, 6; hazelnut: extract, cor a 1, 9, 14; walnut: extract; cow's milk: extract; hen's egg: extract; soybean: extract",
          "timeFrame": "sIgE in blood will be measured every three months during dupilumab treatment"
        },
        {
          "measure": "To evaluate the effect of Dupilumab on the biological activity of IgE for peanut and hazelnut and measurement of biomarkers profile",
          "description": "For patients treated with Dupilumab left over serum is stored except as the patient objects.\n\nPatients treated with Dupilumab asked to participate to the biobank eczema and/or biobank acute inflammation.",
          "timeFrame": "The basophil activation test and the measurement of biomarkers on Luminex at baseline and after at least 28 weeks of dupilumab treatment (e.g. at time of second challenge)"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. AD patients with moderate to severe AD who are indicated for treatment with dupilumab\n2. Peanut, hazelnut, walnut, cow's milk, hen's egg and/or soybean allergy allergic subjects, with a well-documented medical history of reactions after ingestion.Peanut, hazelnut, walnut, cow's milk, hen's egg and/or soybean allergy specific immunoglobulin E (IgE) level (Phadia CAP-system) higher than 0.35 kU/L or a skin prick test of at least 3 mm\n3. Positive double-blind placebo-controlled Food Challenge (DBPCFC) with an eliciting dose before the last dose\n4. Signed Bioday informed consent from subjects\n\nExclusion Criteria:\n\n1. Subjects reacting objectively to the placebo at screening.\n2. Subjects in whom DBCPFC is contra-indicated or in whom DBPCFC is not reliable",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "12 Years",
      "stdAges": [
        "CHILD",
        "ADULT",
        "OLDER_ADULT"
      ],
      "studyPopulation": "AD patients with moderate to severe AD who are indicated for treatment with dupilumab and have comorbid food allergy",
      "samplingMethod": "PROBABILITY_SAMPLE"
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "University Medical Centre Utrecht",
          "city": "Utrecht",
          "zip": "3584 CX",
          "country": "Netherlands",
          "geoPoint": {
            "lat": 52.09083,
            "lon": 5.12222
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D005512",
          "term": "Food Hypersensitivity"
        },
        {
          "id": "D003876",
          "term": "Dermatitis, Atopic"
        }
      ],
      "ancestors": [
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        },
        {
          "id": "D012873",
          "term": "Skin Diseases, Genetic"
        },
        {
          "id": "D030342",
          "term": "Genetic Diseases, Inborn"
        },
        {
          "id": "D009358",
          "term": "Congenital, Hereditary, and Neonatal Diseases and Abnormalities"
        },
        {
          "id": "D003872",
          "term": "Dermatitis"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D017443",
          "term": "Skin Diseases, Eczematous"
        }
      ]
    }
  },
  "hasResults": false
}